Cellectis S.A.

ENXTPA:ALCLS Lagerbericht

Marktkapitalisierung: €169.8m

Cellectis Management

Management Kriterienprüfungen 2/4

Cellectis' CEO is Andre Choulika, appointed in Jan 1999, has a tenure of 25.83 years. total yearly compensation is $876.60K, comprised of 99.8% salary and 0.2% bonuses, including company stock and options. directly owns 1.02% of the company’s shares, worth €1.73M. The average tenure of the management team and the board of directors is 4.3 years and 7.7 years respectively.

Wichtige Informationen

Andre Choulika

Geschäftsführender

US$876.6k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts99.8%
Amtszeit als Geschäftsführer25.8yrs
Eigentum des Geschäftsführers1.0%
Durchschnittliche Amtszeit des Managements4.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder7.7yrs

Jüngste Management Updates

Recent updates

A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)

Feb 07
A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)

Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)

Aug 09
Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)

Is Cellectis (EPA:ALCLS) Using Too Much Debt?

Dec 14
Is Cellectis (EPA:ALCLS) Using Too Much Debt?

Analysts' Revenue Estimates For Cellectis S.A. (EPA:ALCLS) Are Surging Higher

Aug 07
Analysts' Revenue Estimates For Cellectis S.A. (EPA:ALCLS) Are Surging Higher

We Think Some Shareholders May Hesitate To Increase Cellectis S.A.'s (EPA:ALCLS) CEO Compensation

May 26
We Think Some Shareholders May Hesitate To Increase Cellectis S.A.'s (EPA:ALCLS) CEO Compensation

Is Cellectis (EPA:ALCLS) Using Debt Sensibly?

May 17
Is Cellectis (EPA:ALCLS) Using Debt Sensibly?

These Analysts Think Cellectis S.A.'s (EPA:ALCLS) Sales Are Under Threat

Mar 08
These Analysts Think Cellectis S.A.'s (EPA:ALCLS) Sales Are Under Threat

Cellectis (EPA:ALCLS) Is In A Strong Position To Grow Its Business

Feb 16
Cellectis (EPA:ALCLS) Is In A Strong Position To Grow Its Business

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Andre Choulika im Vergleich zu den Einnahmen von Cellectis verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

-US$79m

Mar 31 2024n/an/a

-US$78m

Dec 31 2023US$877kUS$875k

-US$109m

Sep 30 2023n/an/a

-US$92m

Jun 30 2023n/an/a

-US$97m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$744kUS$744k

-US$91m

Sep 30 2022n/an/a

-US$63m

Jun 30 2022n/an/a

-US$78m

Mar 31 2022n/an/a

-US$99m

Dec 31 2021US$879kUS$879k

-US$86m

Sep 30 2021n/an/a

-US$129m

Jun 30 2021n/an/a

-US$121m

Mar 31 2021n/an/a

-US$113m

Dec 31 2020US$1mUS$1m

-US$37m

Sep 30 2020n/an/a

-US$79m

Jun 30 2020n/an/a

-US$66m

Mar 31 2020n/an/a

-US$67m

Dec 31 2019US$1mUS$1m

-US$102m

Vergütung im Vergleich zum Markt: Andre's total compensation ($USD876.60K) is above average for companies of similar size in the French market ($USD462.45K).

Entschädigung vs. Einkommen: Andre's compensation has increased whilst the company is unprofitable.

Geschäftsführer

Andre Choulika (59 yo)

25.8yrs

Amtszeit

US$876,597

Vergütung

Dr. Andre Choulika, Ph.D. is the Founder of Cellectis S.A. and has been its Chief Executive Officer since 1999 and served as its Chairman since 2011 until November 5, 2020. He is the Director of Cellectis...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Andre Choulika
Co-Founder25.8yrsUS$876.60k1.02%
€ 1.7m
David j. Sourdive
Deputy CEOno dataUS$557.84k0.31%
€ 520.0k
Arthur Stril
Interim Chief Financial Officerless than a yearkeine Daten0.0086%
€ 14.5k
Valerie Cros
Principal Financial Officer & Principal Accounting Officer2.9yrskeine Datenkeine Daten
Jean Epinat
Chief Technological Officerno datakeine Datenkeine Daten
Philippe Duchateau
Chief Scientific Officer12.8yrskeine Daten0.043%
€ 73.4k
Marie-Bleuenn Terrier
General Counsel & Secretary of the Board of Directors11.8yrskeine Daten0.031%
€ 51.9k
Pascalyne Wilson
Director of Communicationsno datakeine Datenkeine Daten
Kyung Nam-Wortman
Executive VP & Chief Human Resources Officer4yrskeine Daten0.012%
€ 19.7k
Stephan Reynier
Chief Regulatory & Pharmaceutical Compliance Officerno datakeine Daten0.020%
€ 33.5k
Steven Doares
Senior VP of US Manufacturing & Site Head of the Raleigh4.3yrskeine Daten0.012%
€ 21.2k
Mark Frattini
Chief Medical Officer4.3yrskeine Daten0.017%
€ 28.9k

4.3yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: ALCLS's management team is considered experienced (4.3 years average tenure).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Andre Choulika
Co-Founder25.8yrsUS$876.60k1.02%
€ 1.7m
David j. Sourdive
Deputy CEO24.8yrsUS$557.84k0.31%
€ 520.0k
Jean-Pierre Garnier
Independent Non-Executive Chairman4yrsUS$97.34k0%
€ 0
Laurent Arthaud
Director13.1yrskeine Datenkeine Daten
Pierre Bastid
Independent Director13.1yrsUS$97.34k0.056%
€ 94.8k
Rainer Boehm
Independent Director7.4yrsUS$99.60k0%
€ 0
Dietger Niederwieser
Member of Clinical Advisory Board7.7yrskeine Datenkeine Daten
Kanti Rai
Member of Clinical Advisory Board7.8yrskeine Datenkeine Daten
Catherine Bollard
Member of Clinical Advisory Board7.7yrskeine Datenkeine Daten
Ola Landgren
Member of Clinical Advisory Board7.7yrskeine Datenkeine Daten
Marcela Maus
Member of Clinical Advisory Board7.7yrskeine Datenkeine Daten
Stephan Grupp
Member of Clinical Advisory Board6.2yrskeine Datenkeine Daten

7.7yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrener Vorstand: ALCLS's board of directors are considered experienced (7.7 years average tenure).